QSAM BIOSCIENCES INC News

QSAM Biosciences Announces 1-for-1,000 to 1-for-2,000 Reverse Stock Split Ahead of Merger With Telix >QSAM

Dow JonesApr 16 08:31 ET

Express News | Qsam Announces Reverse Stock Split Ratio Ahead of Merger

Moomoo 24/7Apr 16 08:30 ET

Radiopharmaceutical Market Expected to Reach ~$14B by 2032

Seeking AlphaFeb 25 12:00 ET

QSAM to Be Acquired by Telix for $33.1M Plus $90M CVR

Seeking AlphaFeb 7 16:23 ET

Express News | QSAM Biosciences Signs Definitive Agreement To Be Acquired By Telix Pharmaceuticals; QASM Shareholders To Receive $33.1M In Telix Ordinary Shares and CVRs To Receive Up To $90M In Future Payments Upon Milestonesa

Moomoo 24/7Feb 7 16:01 ET

QSAM Biosciences Signs Definitive Agreement To Be Acquired By Telix Pharmaceuticals >QSAM

Dow JonesFeb 7 16:00 ET

QSAM Biosciences Shares Rise 37% After Merger Term Sheet With Telix Pharma

Dow JonesNov 14, 2023 10:07 ET

QSAM Biosciences Signs Term Sheet To Be Acquired By Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration And Option Fee >QSAM

Dow JonesNov 14, 2023 07:30 ET

QSAM Biosciences Expands Its Study of CycloSam in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center

GlobeNewswireMay 23, 2023 08:00 ET

QSAM Biosciences Receives Patent in Europe for Bone Cancer Treatment

Seeking AlphaApr 26, 2023 08:59 ET

QSAM Biosciences Receives Second Key Patent in Europe for Its Clinical Stage Radiopharmaceutical Drug Candidate, CycloSam

GlobeNewswireApr 26, 2023 08:08 ET

QSAM Biosciences Opens Enrollment of the Second Cohort of Patients in Its Phase 1 Study of CycloSam Targeting Metastatic Bone Cancer

GlobeNewswireApr 5, 2023 08:01 ET

QSAM Biosciences to Provide Updates on Its Clinical Trial at the Emerging Growth Conference on Wednesday, March 22, 2023

GlobeNewswireMar 20, 2023 08:31 ET

QSAM Biosciences Receives Clearance From FDA To Expand Enrollment Criteria In Its Phase 1 Study Of CycloSam Targeting Metastatic Bone Cancer

BenzingaMar 8, 2023 08:05 ET

QSAM Biosciences Completes Enrollment of Initial Cohort in Its Phase 1 Study of CycloSam® Targeting Metastatic Bone Cancer

GlobeNewswireFeb 28, 2023 08:11 ET

QSAM Biosciences Recruits the Ellis Fischel Cancer Center at the University of Missouri as Clinical Trial Site to Further Expand and Advance the Study of CycloSam® for Bone Cancer

GlobeNewswireFeb 22, 2023 08:01 ET

QSAM Biosciences to Present at the Emerging Growth Conference on Wednesday, January 25, 2023

GlobeNewswireJan 23, 2023 08:36 ET

QSAM Biosciences GAAP EPS of -$0.75

Seeking AlphaNov 15, 2022 09:16 ET

QSAM Biosciences Adds Rutgers Cancer Institute of New Jersey as Clinical Trial Site To Expand and Advance Study of CycloSam® in the Treatment of Bone Cancer

GlobeNewswireOct 26, 2022 08:07 ET

QSAM Biosciences Receives Third U.S. Patent for Clinical-Stage Radiopharmaceutical Drug Candidate CycloSam®

GlobeNewswireJul 13, 2022 13:35 ET